Trials / Completed
CompletedNCT00044395
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruboxistaurin mesylate |
Timeline
- Start date
- 2002-07-01
- Completion
- 2005-10-01
- First posted
- 2002-08-30
- Last updated
- 2007-11-06
Locations
39 sites across 9 countries: United States, Australia, Belgium, Denmark, Estonia, Germany, Hungary, Israel, Spain
Source: ClinicalTrials.gov record NCT00044395. Inclusion in this directory is not an endorsement.